Arcutis Biotherapeutics Inc. (ARQT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARQT Stock Price Chart Interactive Chart >
ARQT Price/Volume Stats
| Current price | $16.56 | 52-week high | $27.40 |
| Prev. close | $16.10 | 52-week low | $12.81 |
| Day low | $15.83 | Volume | 584,168 |
| Day high | $16.65 | Avg. volume | 842,739 |
| 50-day MA | $16.08 | Dividend yield | N/A |
| 200-day MA | $19.74 | Market Cap | 1.01B |
Arcutis Biotherapeutics Inc. (ARQT) Company Bio
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.
Latest ARQT News From Around the Web
Below are the latest news stories about ARCUTIS BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate ARQT as an investment opportunity.
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 MonthsArcutis Biotherapeutics Inc (NASDAQ: ARQT) announced new safety and efficacy durability data from its open-label Phase 2 long-term safety study of roflumilast cream (0.3%) in adults with chronic plaque psoriasis. Roflumilast cream 0.3% (Zoryve) is a once-daily steroid-free topical phosphodiesterase-4 inhibitor approved by the FDA in July 2022. The study showed that during the trial, 57.1% (n=185) of roflumilast cream-treated patients achieved an Investigator Global Assessment (IGA) score of clea |
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque PsoriasisDuring the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks)Efficacy was consistent over time across all endpoints, and no lessening of response (no tachyphylaxis) from roflumilast cream was observedLong-term IGA success and Intertriginous-Investigator Global Assessment (I-IGA) success results are consistent with results fr |
The Arcutis Biotherapeutics Inc. (ARQT) had a good session last reading, didn’t it?A share of Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) closed at $13.79 per share on Tuesday, down from $14.48 day before. While Arcutis Biotherapeutics Inc. has underperformed by -4.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT fell by -26.10%, with highs and lows ranging from $27.40 […] |
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 17,050 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 33,550 shares of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee o |
Investing in Arcutis Biotherapeutics Inc. (ARQT) might be a great opportunity, but the stock is a bit overvaluedArcutis Biotherapeutics Inc. (NASDAQ:ARQT) marked $14.59 per share on Thursday, up from a previous closing price of $14.06. While Arcutis Biotherapeutics Inc. has overperformed by 3.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT fell by -28.79%, with highs and lows ranging from $27.40 to […] |
ARQT Price Returns
| 1-mo | 17.78% |
| 3-mo | -5.37% |
| 6-mo | -31.74% |
| 1-year | 15.16% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 11.89% |
| 2022 | -28.64% |
| 2021 | -26.27% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...